TNFRSF17 and Miyoshi myopathy: BI 836909, a novel BCMA-targeted BiTE for the treatment of MM, induces highly specific and efficacious lysis of MM cells in vitro and shows anti-tumor activity in vivo (Table 2) [6, 18, 21, 32].